Emerging Therapies: What Are Promising in the Near Future?

Emerging Therapies: What Are Promising in the Near Future?

The treatment of inflammatory bowel disease has evolved with the development of anti-TNF agents. In spite of long-term effectiveness, many patients do not respond or no longer responds to these drugs. Therefore, the development of new drugs that act on different inflammatory pathways has become nece...

Full description

Bibliographic Details
Main Authors:	Geom Seog Seo, Sung Hee Lee
Format:	Article
Language:	English
Published:	Jin Publishing & Printing Co. 2018-02-01
Series:	The Korean Journal of Gastroenterology
Subjects:	Ulcerative colitis Crohn’s disease Vedolizumab Ustekinumab Tofacitinib
Online Access:	http://www.kjg.or.kr/journal/view.html?doi=10.4166/kjg.2018.71.2.81

Similar Items

Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal
by: J.K. Yamamoto-Furusho, et al.
Published: (2021-01-01)

Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease
by: J.K. Yamamoto-Furusho, et al.
Published: (2021-01-01)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
by: Sophie Restellini, et al.
Published: (2021-03-01)

On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
by: Gian Paolo Caviglia, et al.
Published: (2020-03-01)

Vedolizumab in Inflammatory Bowel Disease: West versus East
by: Prasanta Debnath, et al.
Published: (2021-01-01)

Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
by: Petkau JM, et al.
Published: (2016-03-01)

Current new challenges in the management of ulcerative colitis
by: Tomohiro Fukuda, et al.
Published: (2019-01-01)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
by: Amanda Hansson-Hedblom, et al.
Published: (2018-08-01)

Fever During Anti-integrin Therapy: New Immunodeficiency
by: Eleonora Bonfanti, et al.
Published: (2020-02-01)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
by: Hiroyuki Okamoto, et al.
Published: (2021-01-01)

Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects
by: Sebastian Zundler, et al.
Published: (2017-07-01)

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
by: Dart RJ, et al.
Published: (2017-03-01)

Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
by: Feuerstein, J.D, et al.
Published: (2022)

How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data
by: Ana Gutiérrez, et al.
Published: (2021-01-01)

Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
by: Ahmad Albshesh, et al.
Published: (2021-06-01)

Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
by: Jeong Yeon Kim, et al.
Published: (2020-03-01)

Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis
by: Raúl Vicente Olmedo-Martín, et al.

Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice
by: M. V. Shapina, et al.
Published: (2020-02-01)

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
by: Lieven Pouillon, et al.
Published: (2019-05-01)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
by: Timo Rath, et al.
Published: (2018-07-01)

High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
by: Manuel Sutter, et al.
Published: (2021-08-01)

The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database
by: Jung, S.H, et al.
Published: (2022)

The use of Tofacitinib in the treatment of inflammatory bowel disease
by: E L Nasonov, et al.
Published: (2019-02-01)

BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS
by: E. A. Pyadushkina
Published: (2017-05-01)

Immunoglobulin A vasculitis in an adult patient receiving vedolizumab therapy for ulcerative colitis: A case report
by: http://www.mdpub.net/index.php?fulltxt=68728&fulltxtj=172&fulltxtp=172-1570485169.pdf
Published: (2019-11-01)

Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab
by: Diana Martins, et al.
Published: (2018-02-01)

Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives
by: Gubatan J, et al.
Published: (2021-08-01)

Ustekinumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum
by: Hayakawa, T., et al.
Published: (2022)

Ustekinumab in patients with Crohn’s disease with extraintestinal manifestations (psoriasis)
by: P. A. Makarchuk, et al.
Published: (2020-10-01)

Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy
by: Tran V, et al.
Published: (2019-05-01)

Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data
by: Varyani F, et al.
Published: (2019-12-01)

Tofacitinib: An Option for Acute Severe Ulcerative Colitis?
by: Sara Santos, et al.
Published: (2021-03-01)

Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK
by: Wilson MR, et al.
Published: (2017-10-01)

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review
by: Ulf Helwig, et al.
Published: (2020-07-01)

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
by: Rawla P, et al.
Published: (2018-05-01)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
by: Benjamin Crooks, et al.
Published: (2020-03-01)

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China
by: Ting Zhou, et al.
Published: (2021-08-01)

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
by: Choon Jin Ooi, et al.
Published: (2021-01-01)

Human herpesvirus 8-associated colonic Kaposi’s sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literature
by: Valerio Papa, et al.
Published: (2020-03-01)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
by: Friederike Fuchs, et al.
Published: (2017-07-01)